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background:  Observational studies evaluating the possible interaction between proton pump inhibitors (PPIs) and clopidogrel have shown mixed 
results. We conducted a systematic review comparing the effectiveness and safety of individual PPIs in patients with coronary artery disease (CAD) 
taking clopidogrel.
methods: Studies performed from 1995 to 2013 were screened for inclusion. Data were extracted and study quality was graded for 33 potential 
studies. For those studies where follow up period, outcomes, and multivariable adjustment were comparable, meta-analysis was performed.
results: The odds or hazard ratios for the composite of cardiovascular (CV) death, myocardial infraction, and stroke at 1 year were reported in 6 
observational studies with data on individual PPIs. Random-effects meta-analyses of the 6 studies revealed an increased risk for adverse CV events 
for those taking pantoprazole (HR 1.45; 1.17-1.80), lansoprazole (HR 1.29; 1.09-1.52), or esomeprazole (HR 1.27; 1.02-1.58) compared with 
patients on no PPI. This association was not significant for omeprazole (HR 1.16; 0.93-1.44).
Conclusions: Several frequently used PPIs, previously thought to be safe for concomitant use with clopidogrel, were associated with greater risk of 
adverse CV events. While the data are observational, they highlight the need for randomized clinical trials to evaluate the safety of concomitant PPI 
and clopidogrel use in patients with CAD.
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